Disease Landscape and Forecast Insights

Hepatocellular carcinoma remains a challenging disease with a complex underlying etiology. While angiogenesis inhibitors including Nexavar (Bayer / Amgen), Stivarga (Bayer), Lenvima (Eisai / Merck…

The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma…

Hepatocellular carcinoma, the most common type of liver cancer, occurs as a result of chronic liver cirrhosis. It has a five-year survival rate of only 18%. First-line advanced hepatocellular…

Hepatocellular carcinoma, the most common type of liver cancer, occurs as a result of chronic liver cirrhosis. It has a five-year survival rate of only 18%. First-line advanced hepatocellular…

Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx) was the only drug approved for advanced disease…

The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma…

Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx) was the only drug approved for advanced disease…

Hepatocellular carcinoma, the most common type of primary liver cancer, occurs as a results of chronic liver cirrhosis and has a five-year survival rate of only 18%. First-line advanced…

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was…

MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised to experience substantial market growth. Availability of systemic targeted drugs is limited, with only three agents…

Market Outlook: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, with the majority of cases arising from underlying liver cirrhosis. Treatment of HCC incorporates a variety…

Hepatocellular carcinoma is a primary malignancy of the liver; the majority of cases arise from underlying liver cirrhosis. Treatment of hepatocellular carcinoma incorporates a variety of…